Please login to the form below
Outcomes-based payment
This page shows the latest Outcomes-based payment news and features for those working in and with pharma, biotech and healthcare.
Bluebird bio launches beta thalassaemia gene therapy Zynteglo in Germany
Will offer treatment via an outcomes-based payment model. Bluebird bio has launched its innovative gene therapy Zynteglo in Germany, its first commercial market. ... As it had previously planned, bluebird has entered into an outcomes-based payment
Latest news
-
Who's calling the shots in European healthcare?
Sustainable solutions? So what does Natsis think about new payment models being put forward by pharma and healthcare systems, such as pay-for-performance and outcomes-based payment, in tandem with ... that make the interventions that deliver the outcomes
-
Bluebird puts €1.57m price on gene therapy Zynteglo
US biotech pioneering outcomes-based payment in Europe. Bluebird Bio’s gene therapy treatment for beta thalassemia Zynteglo is to be priced at 1.575m ($1.76m) in Europe, where the ... Bluebird has learnt from that failure, and has been careful to lay
-
A first for Bluebird and Europe as gene therapy Zynteglo approved
The approval is not only special for Boston, Mass-based Bluebird Bio, but also for Europe, as the company chose to file its gene therapy with the European Medicines Agency first, ... Bluebird’s plans involves all but the first payment being paid based
-
Novartis secures US approval - and payers’ blessing – for $2m gene therapy Zolgensma
new blockbuster product – via an entirely new model of outcomes-based instalment payments. ... Among these payers is Harvard Pilgrim Health Care, which has made a name for itself in pioneering outcomes-based deals with the industry.
-
NHS England wants money-back guarantee on Orkambi
Vertex has been resisting any outcomes-based link to payment for some time, and looks to be opposed to this latest offer as well.
More from news
Approximately 2 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Gene therapy market access Q&A
What do you see as the big barriers to adoption of novel payment mechanisms in Europe? ... Historically, there’s been a fair amount of reluctance to adopt novel payment mechanisms like outcomes-based reimbursement schemes, often because of concerns
-
Managing medication non-adherence
In this era of value-based payment models becoming mainstream, this is certainly a triple whammy of benefits for all pharma companies to aim for. ... Start gathering data quickly. Providing evidence of improved outcomes based on digital biomarkers, and
-
Reaching new heights
Providers in more parts of the world will be subject to performance or outcomes-based contracts and payment systems, bringing sharper scrutiny to patient outcomes and costs associated with patient care. ... More healthcare will be delivered using
-
Healthcare business and operating models redefined
outcomes. When payment or reimbursement is based on inputs, there is an adverse incentive to do as little as possible and receive the same compensation. ... Technology as a solution. Technology is opening up solutions. For payment based on outputs, a
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Event: World Pharma Pricing and Market Access Congress
To allow negotiations to move forward and ensure more timely access to patients, we need to look at using innovative payment models such as outcomes-based contracting and find ways of
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
- Presenting Outstanding Outcomes from HCP Education in Multiple Myeloma at IMS in Athens
No results were found
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
